Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.39
RHHBY's Cash to Debt is ranked lower than
89% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: 56.38 vs. RHHBY: 0.39 )
Ranked among companies with meaningful Cash to Debt only.
RHHBY' s Cash to Debt Range Over the Past 10 Years
Min: 0.36  Med: 1.51 Max: N/A
Current: 0.39
Equity to Asset 0.28
RHHBY's Equity to Asset is ranked lower than
85% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. RHHBY: 0.28 )
Ranked among companies with meaningful Equity to Asset only.
RHHBY' s Equity to Asset Range Over the Past 10 Years
Min: 0.1  Med: 0.38 Max: 0.59
Current: 0.28
0.1
0.59
Interest Coverage 16.00
RHHBY's Interest Coverage is ranked lower than
76% of the 364 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RHHBY: 16.00 )
Ranked among companies with meaningful Interest Coverage only.
RHHBY' s Interest Coverage Range Over the Past 10 Years
Min: 5.94  Med: 10.84 Max: N/A
Current: 16
F-Score: 5
Z-Score: 3.67
M-Score: -2.86
WACC vs ROIC
6.41%
30.44%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 27.42
RHHBY's Operating margin (%) is ranked higher than
90% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. RHHBY: 27.42 )
Ranked among companies with meaningful Operating margin (%) only.
RHHBY' s Operating margin (%) Range Over the Past 10 Years
Min: 24  Med: 28.74 Max: 35.01
Current: 27.42
24
35.01
Net-margin (%) 17.58
RHHBY's Net-margin (%) is ranked higher than
87% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: -75.29 vs. RHHBY: 17.58 )
Ranked among companies with meaningful Net-margin (%) only.
RHHBY' s Net-margin (%) Range Over the Past 10 Years
Min: 15.22  Med: 18.73 Max: 23.86
Current: 17.58
15.22
23.86
ROE (%) 46.10
RHHBY's ROE (%) is ranked higher than
98% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. RHHBY: 46.10 )
Ranked among companies with meaningful ROE (%) only.
RHHBY' s ROE (%) Range Over the Past 10 Years
Min: 19.94  Med: 45.85 Max: 102.95
Current: 46.1
19.94
102.95
ROA (%) 12.07
RHHBY's ROA (%) is ranked higher than
92% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. RHHBY: 12.07 )
Ranked among companies with meaningful ROA (%) only.
RHHBY' s ROA (%) Range Over the Past 10 Years
Min: 10.33  Med: 12.78 Max: 17.58
Current: 12.07
10.33
17.58
ROC (Joel Greenblatt) (%) 64.53
RHHBY's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -356.62 vs. RHHBY: 64.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RHHBY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 51.65  Med: 64.13 Max: 84.52
Current: 64.53
51.65
84.52
Revenue Growth (3Y)(%) 3.20
RHHBY's Revenue Growth (3Y)(%) is ranked lower than
51% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.40 vs. RHHBY: 3.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RHHBY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.7  Med: 5.20 Max: 394
Current: 3.2
-3.7
394
EBITDA Growth (3Y)(%) -0.40
RHHBY's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.10 vs. RHHBY: -0.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RHHBY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.8  Med: 16.50 Max: 322.9
Current: -0.4
-2.8
322.9
EPS Growth (3Y)(%) -2.70
RHHBY's EPS Growth (3Y)(%) is ranked higher than
52% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. RHHBY: -2.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RHHBY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.2  Med: 8.50 Max: 340.9
Current: -2.7
-3.2
340.9
» RHHBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

RHHBY Guru Trades in Q2 2015

Ken Fisher 14,211,412 sh (+409.71%)
Mairs and Power 2,712,376 sh (+0.31%)
» More
Q3 2015

RHHBY Guru Trades in Q3 2015

Ken Fisher 14,538,602 sh (+2.30%)
Mairs and Power 2,712,985 sh (+0.02%)
» More
Q4 2015

RHHBY Guru Trades in Q4 2015

Ken Fisher 14,630,453 sh (+0.63%)
Mairs and Power 2,714,500 sh (+0.06%)
» More
Q1 2016

RHHBY Guru Trades in Q1 2016

Ken Fisher 14,906,191 sh (+1.88%)
Mairs and Power 2,723,637 sh (+0.34%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NYSE:NVO, NAS:AMGN, NAS:GILD, NAS:CELG, NAS:BIIB, OTCPK:CSLLY, NAS:REGN, OTCPK:SHPGF, NYSE:BXLT, NAS:ALXN, NAS:VRTX, OTCPK:ALIOY, NAS:INCY, OTCPK:GIKLY, NAS:BMRN, OTCPK:NVZMY, OTCPK:UCBJY, NAS:MDVN, OTCPK:GMXAY, NAS:JAZZ » details
Traded in other countries:RHO5.Germany, ROG N.Mexico, RO.Switzerland, 0QOK.UK,
Roche Holding AG is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience.

Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience. It has more than 66 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals and Chugai, whereas Genentech as the former third segment has been integrated into Roche Pharmaceuticals. The Diagnostics Division consists of the following four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Top Ranked Articles about Roche Holding AG

Does Biotech’s Recent Bounce Have Legs? Examining 3 Big Pharma stocks that dominate the making of cancer-fighting treatments
The beleaguered biotechology sector, which has endured political controversy amid charges of price gouging, is now on an upward trajectory. The Nasdaq Biotechnology Index, after falling 17.46% year to date, has jumped 9.04% over the past month. Read more...
Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Largest trades in second quarter include also Infosys and Alibaba
Ken Fisher (Trades, Portfolio) is the chief executive officer and chief investment officer of Fisher Investments, which offers an array of educational resources to its 27,000-plus private clients —including quarterly reports, in-person seminars and regular phone communication. Fisher Investments extends these educational resources to the public through a series of investing guides, online videos and daily commentary at MarketMinder.com. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 24.14
RHHBY's P/E(ttm) is ranked higher than
60% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.89 vs. RHHBY: 24.14 )
Ranked among companies with meaningful P/E(ttm) only.
RHHBY' s P/E(ttm) Range Over the Past 10 Years
Min: 13.05  Med: 19.74 Max: 37.26
Current: 24.14
13.05
37.26
Forward P/E 16.29
RHHBY's Forward P/E is ranked higher than
62% of the 69 Companies
in the Global Biotechnology industry.

( Industry Median: 20.16 vs. RHHBY: 16.29 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.14
RHHBY's PE(NRI) is ranked higher than
59% of the 231 Companies
in the Global Biotechnology industry.

( Industry Median: 29.89 vs. RHHBY: 24.14 )
Ranked among companies with meaningful PE(NRI) only.
RHHBY' s PE(NRI) Range Over the Past 10 Years
Min: 13.05  Med: 19.74 Max: 37.08
Current: 24.14
13.05
37.08
Price/Owner Earnings (ttm) 17.02
RHHBY's Price/Owner Earnings (ttm) is ranked higher than
74% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 34.05 vs. RHHBY: 17.02 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
RHHBY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.69  Med: 15.39 Max: 29.45
Current: 17.02
9.69
29.45
P/B 10.09
RHHBY's P/B is ranked lower than
85% of the 1024 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. RHHBY: 10.09 )
Ranked among companies with meaningful P/B only.
RHHBY' s P/B Range Over the Past 10 Years
Min: 2.64  Med: 11.32 Max: 22.21
Current: 10.09
2.64
22.21
P/S 4.33
RHHBY's P/S is ranked higher than
75% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 12.56 vs. RHHBY: 4.33 )
Ranked among companies with meaningful P/S only.
RHHBY' s P/S Range Over the Past 10 Years
Min: 2.33  Med: 4.08 Max: 6.05
Current: 4.33
2.33
6.05
PFCF 19.19
RHHBY's PFCF is ranked higher than
63% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 27.20 vs. RHHBY: 19.19 )
Ranked among companies with meaningful PFCF only.
RHHBY' s PFCF Range Over the Past 10 Years
Min: 8.71  Med: 17.27 Max: 36.73
Current: 19.19
8.71
36.73
POCF 14.06
RHHBY's POCF is ranked higher than
68% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 22.58 vs. RHHBY: 14.06 )
Ranked among companies with meaningful POCF only.
RHHBY' s POCF Range Over the Past 10 Years
Min: 7.05  Med: 13.73 Max: 21.96
Current: 14.06
7.05
21.96
EV-to-EBIT 17.26
RHHBY's EV-to-EBIT is ranked higher than
55% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 22.27 vs. RHHBY: 17.26 )
Ranked among companies with meaningful EV-to-EBIT only.
RHHBY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 13.90 Max: 24.3
Current: 17.26
7.8
24.3
EV-to-EBITDA 13.50
RHHBY's EV-to-EBITDA is ranked higher than
59% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 18.12 vs. RHHBY: 13.50 )
Ranked among companies with meaningful EV-to-EBITDA only.
RHHBY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.5  Med: 11.90 Max: 21.8
Current: 13.5
6.5
21.8
PEG 16.53
RHHBY's PEG is ranked lower than
92% of the 89 Companies
in the Global Biotechnology industry.

( Industry Median: 2.25 vs. RHHBY: 16.53 )
Ranked among companies with meaningful PEG only.
RHHBY' s PEG Range Over the Past 10 Years
Min: 0.37  Med: 1.69 Max: 18.57
Current: 16.53
0.37
18.57
Shiller P/E 22.05
RHHBY's Shiller P/E is ranked higher than
80% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 55.74 vs. RHHBY: 22.05 )
Ranked among companies with meaningful Shiller P/E only.
RHHBY' s Shiller P/E Range Over the Past 10 Years
Min: 18.37  Med: 23.88 Max: 35.52
Current: 22.05
18.37
35.52
Current Ratio 1.19
RHHBY's Current Ratio is ranked lower than
87% of the 903 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. RHHBY: 1.19 )
Ranked among companies with meaningful Current Ratio only.
RHHBY' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 2.37 Max: 3.75
Current: 1.19
1.19
3.75
Quick Ratio 0.86
RHHBY's Quick Ratio is ranked lower than
87% of the 903 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. RHHBY: 0.86 )
Ranked among companies with meaningful Quick Ratio only.
RHHBY' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.97 Max: 3.22
Current: 0.86
0.86
3.22
Days Inventory 179.07
RHHBY's Days Inventory is ranked lower than
66% of the 442 Companies
in the Global Biotechnology industry.

( Industry Median: 128.95 vs. RHHBY: 179.07 )
Ranked among companies with meaningful Days Inventory only.
RHHBY' s Days Inventory Range Over the Past 10 Years
Min: 143.33  Med: 159.24 Max: 186.16
Current: 179.07
143.33
186.16
Days Sales Outstanding 60.32
RHHBY's Days Sales Outstanding is ranked higher than
52% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 62.68 vs. RHHBY: 60.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
RHHBY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.32  Med: 74.15 Max: 84.09
Current: 60.32
60.32
84.09
Days Payable 75.72
RHHBY's Days Payable is ranked higher than
60% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 57.78 vs. RHHBY: 75.72 )
Ranked among companies with meaningful Days Payable only.
RHHBY' s Days Payable Range Over the Past 10 Years
Min: 49.43  Med: 60.53 Max: 78.64
Current: 75.72
49.43
78.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.20
RHHBY's Dividend Yield is ranked higher than
86% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 1.22 vs. RHHBY: 3.20 )
Ranked among companies with meaningful Dividend Yield only.
RHHBY' s Dividend Yield Range Over the Past 10 Years
Min: 0.99  Med: 2.88 Max: 4.55
Current: 3.2
0.99
4.55
Dividend Payout 0.74
RHHBY's Dividend Payout is ranked lower than
87% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. RHHBY: 0.74 )
Ranked among companies with meaningful Dividend Payout only.
RHHBY' s Dividend Payout Range Over the Past 10 Years
Min: 0.21  Med: 0.55 Max: 0.78
Current: 0.74
0.21
0.78
Dividend Growth (3y) 5.60
RHHBY's Dividend Growth (3y) is ranked lower than
53% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. RHHBY: 5.60 )
Ranked among companies with meaningful Dividend Growth (3y) only.
RHHBY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 10.80 Max: 27.3
Current: 5.6
0
27.3
Forward Dividend Yield 3.23
RHHBY's Forward Dividend Yield is ranked higher than
85% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 1.20 vs. RHHBY: 3.23 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.26
RHHBY's Yield on cost (5-Year) is ranked higher than
85% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 1.39 vs. RHHBY: 4.26 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
RHHBY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.32  Med: 3.84 Max: 6.06
Current: 4.26
1.32
6.06
3-Year Average Share Buyback Ratio 0.40
RHHBY's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. RHHBY: 0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RHHBY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 78.5
Current: 0.4
0
78.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.65
RHHBY's Price/Projected FCF is ranked higher than
77% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. RHHBY: 1.65 )
Ranked among companies with meaningful Price/Projected FCF only.
RHHBY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.12  Med: 1.73 Max: 3.64
Current: 1.65
1.12
3.64
Price/Median PS Value 1.04
RHHBY's Price/Median PS Value is ranked lower than
59% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: 0.94 vs. RHHBY: 1.04 )
Ranked among companies with meaningful Price/Median PS Value only.
RHHBY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.63  Med: 1.00 Max: 1.3
Current: 1.04
0.63
1.3
Earnings Yield (Greenblatt) (%) 5.73
RHHBY's Earnings Yield (Greenblatt) (%) is ranked higher than
88% of the 1104 Companies
in the Global Biotechnology industry.

( Industry Median: -9.68 vs. RHHBY: 5.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RHHBY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.1  Med: 7.20 Max: 12.8
Current: 5.73
4.1
12.8
Forward Rate of Return (Yacktman) (%) 6.89
RHHBY's Forward Rate of Return (Yacktman) (%) is ranked lower than
62% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 14.22 vs. RHHBY: 6.89 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
RHHBY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 4.6  Med: 13.90 Max: 53.1
Current: 6.89
4.6
53.1

More Statistics

Revenue (TTM) (Mil) $52,253
EPS (TTM) $ 1.34
Beta0.59
Short Percentage of Float0.00%
52-Week Range $29.89 - 36.50
Shares Outstanding (Mil)6,816.16

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 53,327 57,027 65,059
EPS ($) 1.96 2.11 2.50
EPS w/o NRI ($) 1.96 2.11 2.50
EPS Growth Rate
(3Y to 5Y Estimate)
8.66%
Dividends Per Share ($) 1.06 1.14 1.20
» More Articles for RHHBY

Headlines

Articles On GuruFocus.com
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016 
Invesco Adds to Holdings in Investment, Financial Services Companies Jul 01 2016 
Bearish Sentiment in Becton Dickinson's Stock Apr 27 2016 
Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
Invesco European Growth Fund Adds to More Than 40 Existing Stakes Apr 04 2016 
Invesco European Growth Fund Adds to 7 Stakes Jan 26 2016 
Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Oct 12 2015 
Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
Ken Fisher's most weighted buys in Q2 2015 Jul 28 2015 

More From Other Websites
Dissecting Roche’s Performance across Its Segments Jul 22 2016
Reasons behind Roche’s Better-than-Expected 2Q16 Performance Jul 22 2016
Amgen, Allergan biosimilar found as effective as Roche cancer drug Jul 21 2016
[$$] Roche says UK faces losing lead in medical research after Brexit Jul 21 2016
Roche CEO Confident Business Will Succeed Despite Turmoil Jul 21 2016
Roche CEO Confident Business Will Succeed Despite Turmoil Jul 21 2016
[$$] Roche Sales Rise on Cancer Drugs Jul 21 2016
Roche Beats First-Half Forecasts as Cancer Drug Sales Rise Jul 21 2016
Pairing New Cancer Drugs With Older Ones Bolsters Roche Profit Jul 21 2016
What Are Roche’s Truest Growth Opportunities? Jul 19 2016
Inside Roche’s Strategy to Offset Revenue Declines Jul 19 2016
Roche's Gazyva Fails in Phase III B-cell Lymphoma Study Jul 18 2016
Gauging Growth Expectations for Roche in 2Q16 and 2016 Jul 18 2016
Roche Blood Cancer Medicine Fails to Show Major Improvement Jul 18 2016
Genentech Provides Update on Phase III Study of Gazyva® in People With Previously Untreated Diffuse... Jul 18 2016
How Much Upward Potential Does Roche Really Have? Jul 15 2016
CoaguChek® PT/ INR devices for use at the point of care and for patient self-testing remain a safe... Jul 15 2016
Amgen and Daiichi Sankyo Team Up for Biosimilars in Japan Jul 14 2016
Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)